Sep. 23 at 8:38 PM
$PMN PMN310 targets soluble amyloid-beta oligomers (not plaque), a design meant to reduce ARIA risk and possibly improve efficacy vs. plaque-binding drugs; the program is in a Phase 1b (PRECISE-AD) dose-escalation study that recently cleared its DSMB to proceed to the final dose cohort, with 6-month interim data guided for Q2 2026 and 12-month topline in Q4 2026and the FDA granted Fast Track in July 2025, which can ease interactions and speed review if data are positive. Financially, this remains high risk: ProMIS reported
$4.5M cash at 6/30/25 and then raised an additional ~
$21.6M gross in July 2025 through a mix of offerings and warrant exercises; even so, the companyβs own 10-Q flags going-concern risk and indicates that cash (including July proceeds) is not sufficient for 12 months without further financing, implying likely dilution ahead unless they secure a partner.
